Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Clinical trial NCT06120140 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06120140
Sponsor: Janssen Research & Development, LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2024-02-16
Primary completion: 2027-05-31
Enrollment: 305

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.